Eila Skinner, MD
Urology · Stanford, CANPI 1588673941
Payments from drug & device makers
What this record shows
This record is dominated by education: $1,080 of the $1,742 with a category attached, or 62.0%. Olympus Corporation Of The Americas accounts for 62.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $1,229 and has fallen 98.6% since, to $18 in 2025. That places this record below the midpoint for urology clinicians in CA, where the typical reported total is $2,485.
Across 8 payments — averaging $217.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$1K
- Urogen Pharma, Inc.$242
- Genentech USA, Inc.$149
- Immunitybio, Inc.$117
- Astellas Pharma US Inc$79
- Genentech, Inc.$57
- plus $18 from 1 others
Across 34 payments — averaging $7124.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$242K
What the payments were for
- Food & beverage$66238%
- Education$1,08062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 1 | $1,080 |
| Urogen Pharma, Inc. | 2 | $242 |
| Genentech USA, Inc. | 1 | $149 |
| Immunitybio, Inc. | 1 | $117 |
| Astellas Pharma US Inc | 1 | $79 |
| Genentech, Inc. | 1 | $57 |
| Ambu Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Olympus Cysto-Resection$1,080
- Olympus Cystoscopes$1,080
- Olympus Resection Disposables$1,080
- TECENTRIQ$149
- ANKTIVA$117
How this compares
$1,742 in reported general payments places this provider in the 40th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gentamicin Sulfate | 53 | $1,596 |
Paid to pharmacies, not to this prescriber.
Other urology in Stanford
- Benjamin ChungStanford$80K
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.